![]() ![]() He also serves on the Advisory Board of the Tsinghua University School of Economics and Management in Beijing and on the Executive Committee of the Partnership for New York City. In addition, he serves on the boards of the Museum of Modern Art, the Council on Foreign Relations and the International Rescue Committee. ![]() He serves as a member of the Board of Trustees of New York University (NYU) and the World Economic Forum, and is Co-Chairman of the NYU Langone Medical Center Board of Trustees. Fink was a member of the Management Committee and a Managing Director of The First Boston Corporation. BlackRock's mission is to help our clients build better financial futures and the firm is trusted to manage more money than any other investment company in the world. He and seven partners founded BlackRock in 1988, and under his leadership, the firm has grown into a global leader in investment and technology solutions. Fink is Chairman and Chief Executive Officer of BlackRock. Metacrine has received authorization from the U.S.Laurence D. #Mtmr stock trial#(NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. 11, 2022 (GLOBE NEWSWIRE) - Metacrine, Inc. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan These help us to improve your visit to our website. Instead, it pushed their FXR agonist, MET642, into a Phase 2 trial for inflammatory bowel disease. Like most websites, we use cookies to make browsing our site as convenient as possible. The same technology allows you to turn the system on and off. While NASH was originally Metacrine's priority, the Company abandoned the program back in October after a toxicology study flagged potential delay.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |